Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS One. 2012;7(8):e42754. doi: 10.1371/journal.pone.0042754. Epub 2012 Aug 13.
The blood-retinal barrier (BRB) prevents most systemically-administered drugs from reaching the retina. This study investigated whether burst ultrasound applied with a circulating microbubble agent can disrupt the BRB, providing a noninvasive method for the targeted delivery of systemically administered drugs to the retina. To demonstrate the efficacy and reversibility of such a procedure, five overlapping targets around the optic nerve head were sonicated through the cornea and lens in 20 healthy male Sprague-Dawley rats using a 690 kHz focused ultrasound transducer. For BRB disruption, 10 ms bursts were applied at 1 Hz for 60 s with different peak rarefactional pressure amplitudes (0.81, 0.88 and 1.1 MPa). Each sonication was combined with an IV injection of a microbubble ultrasound contrast agent (Definity). To evaluate BRB disruption, an MRI contrast agent (Magnevist) was injected IV immediately after the last sonication, and serial T1-weighted MR images were acquired up to 30 minutes. MRI contrast enhancement into the vitreous humor near targeted area was observed for all tested pressure amplitudes, with more signal enhancement evident at the highest pressure amplitude. At 0.81 MPa, BRB disruption was not detected 3 h post sonication, after an additional MRI contrast injection. A day after sonication, the eyes were processed for histology of the retina. At the two lower exposure levels (0.81 and 0.88 MPa), most of the sonicated regions were indistinguishable from the control eyes, although a few tiny clusters of extravasated erythrocytes (petechaie) were observed. More severe retinal damage was observed at 1.1 MPa. These results demonstrate that focused ultrasound and microbubbles can offer a noninvasive and targeted means to transiently disrupt the BRB for ocular drug delivery.
血视网膜屏障 (BRB) 阻止了大多数全身给药的药物到达视网膜。本研究旨在探讨爆破式超声联合循环微泡剂是否可以破坏 BRB,从而为全身给药靶向递送至视网膜提供一种非侵入性方法。为了证明这种方法的有效性和可逆性,本研究使用 690 kHz 聚焦超声换能器通过角膜和晶状体对视神经头部周围的五个重叠靶点进行了超声处理。为了破坏 BRB,采用 1 Hz 的 10 ms 爆破模式,施加不同的峰值稀疏压力幅值(0.81、0.88 和 1.1 MPa),持续 60 s。每次超声处理均与 IV 注射微泡超声造影剂(Definity)联合进行。为了评估 BRB 破坏情况,在最后一次超声处理后立即 IV 注射 MRI 造影剂(Magnevist),并在 30 分钟内连续采集 T1 加权 MRI 图像。在所有测试压力幅值下,均观察到靶向区域附近玻璃体中 MRI 造影剂增强,在最高压力幅值下信号增强更为明显。在 0.81 MPa 下,在最后一次超声处理后 3 小时,未检测到 BRB 破坏,随后再次进行 MRI 造影剂注射。在超声处理后一天,对眼睛进行视网膜组织学处理。在较低的两个暴露水平(0.81 和 0.88 MPa)下,大多数超声处理区域与对照眼无明显区别,尽管观察到一些微小的红细胞外渗(瘀点)簇。在 1.1 MPa 时观察到更严重的视网膜损伤。这些结果表明,聚焦超声联合微泡可以提供一种非侵入性和靶向的方法,短暂破坏 BRB 以实现眼部药物递送。